AlphAIAlphAI — Financial news for AI agents
tipranks.comOCT 71 min read$VKTX

Viking Therapeutics price target lowered to $85 from $87 at Truist

Truist analyst Gregory Renza reduced Viking Therapeutics' price target to $85 from $87, maintaining a Buy rating. The firm expects biotech sector strength but cautions about valuation, macroeconomic factors, and policy risks. Truist prefers companies with clear revenue growth and differentiated profiles.

Original reporting
tipranks.com
Published Oct 7, 2026, 1:06 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 7, 2026, 5:35 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefFinancial news
Primary signal
$VKTX
Bearish
high confidence
Mentioned
$VKTX
Relevance
7/10
AlphAI data visualization · based on tipranks.com
Decision brief

The 30-second read

$VKTXBearishMed
01

Why it matters

The price‑target reduction reflects tighter expectations for VKTX's near‑term performance.

02

Market read

A modest analyst downgrade that may prompt short‑term price adjustments for VKTX.

03

What to watch

Upcoming Q3 results and obesity franchise progress could offset the target reduction.

Relevance 7/10Novelty 6/10Timing: today

Background

Truist analyst Gregory Renza adjusted his valuation model for biotech names and previewed VKTX's Q3 results.

Company-level read

Ticker impact

$VKTXBearishHigh confidence
Context

Truist lowered Viking Therapeutics' price target to $85 from $87, maintaining a Buy rating.

Expected impact

potential downside as the market prices in the lower target

Evidence & confidence

Target reduction signals reduced upside expectations; investors may trim positions.

Market effects

Sector

Biotech sector may see modest pressure as analysts tighten valuations.

Regional

Limited to U.S. biotech investors.

Global

Low; impact confined to VKTX and similar small‑cap biotech stocks.

Counterpoint

What could challenge this read

The target cut may be overly cautious; VKTX could still rally on upcoming data.

Key entities

  • Analyst Firm
    Truist

    Provided the price‑target update and Buy rating.

  • Company
    Viking Therapeutics

    Subject of the price‑target change.

Read at source← All news

Related articles

OCT 6
$VKTXMedAI 8/10

Viking Therapeutics initiates oral maintenance dosing study

Viking Therapeutics (VKTX) began Part 2 of a maintenance dosing study for VK2735, its obesity treatment. The trial will test oral and subcutaneous dosing regimens in 195 adults with obesity. Part 1 showed positive results. Part 2 results are expected in 2027. Viking is also running two Phase 3 studies, VANQUISH-1 and VANQUISH-2, for subcutaneous VK2735.

investing.com2 min
OCT 5
$VKTXHighAI 8/10

Significant stock movers of September: Viking soars, Longeveron slides

Viking Therapeutics (VKTX) rose 24% in September after positive Phase 1 data for VK2735, a weight-loss drug, but ended the month down 3.18% due to a $575M financing. Longeveron (LGVN) fell 64% after its stem cell therapy failed a Phase 2b trial, triggering a strategic review. The broader biotech sector declined 3.5% in September.

biospace.com3 min
OCT 4
$VKTXMedAI 8/10

Viking Therapeutics (VKTX) On Fresh VK2735 Data And New Funding Still Looks Pricey

Viking Therapeutics (VKTX) reported positive top-line data for its VK2735 obesity maintenance study and raised over US$500m. Despite this, the share price has declined 15.8% in 7 days and 22.7% in 90 days, trading at US$29.94. The company's P/B ratio of 8.6x is significantly higher than its peers, suggesting high expectations for future value creation. A DCF model estimates the stock's value at US$7.34, indicating potential overvaluation.

simplywall.st2 min